Related Experiment Videos
Association between plasma PCSK9 and gamma-glutamyl transferase levels in diabetic patients
Bertrand Cariou1, Maëlle Le Bras, Cédric Langhi
1INSERM, U915, Nantes F-44000, France. bertrand.cariou@univ-nantes.fr
Background:
Proprotein convertase subtilisin kexin type 9 (PCSK9) is a secreted proprotein convertase acting as a natural inhibitor of the low-density lipoprotein (LDL) receptor. Here, we prospectively investigated the relationship between the circulating levels of PCSK9 and metabolic parameters in 117 diabetic patients.
Results:
Plasma PCSK9 level was significantly higher in type 2 than in type 1 diabetes (P=0.04), in diabetic patients under statins (P<10(-4)) and in those with macrovascular complications (P=0.002). Univariable regression analysis revealed that plasma PCSK9 level correlated positively with age (P=0.003), body mass index (P=0.04), systolic blood pressure (SBP) (P=0.01), gamma-glutamyl transferase (GGT) levels (P=0.0002) and statin treatment (P=0.001). In a multivariable linear regression analysis, PCSK9 correlated positively with GGT level (beta=21.91, P=0.0019) after adjustment for gender, age, type of diabetes, statin treatment, BMI, SBP and HbA1c.
Conclusion:
PCSK9 level was independently associated with GGT level in diabetic patients, suggesting potential interaction between PCSK9 and liver function.
Related Concept Videos
Dipeptidyl Peptidase 4 Inhibitors
Diabetic Nephropathy
Hyperglycemia
Pharmacogenomics: Identification of New Drug Targets
Diabetes Mellitus: Type 2 and Gestational
Diabetes: Symptoms, Diagnosis, and Complications